[Updated, 2/16/18, 9:10 a.m. See below.] Using software to speed up drug discovery isn’t a new idea, but it’s generating more interest thanks to artificial intelligence. BioXcel Therapeutics is trying to parlay that momentum into an initial public stock offering to fund human studies on a pair of drugs it found with the help of … Continue reading “With IPO, BioXcel Looks to Fund AI-Fueled Drug Discovery Work”
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
Eli Lilly Builds Case to Expand Immune Drug’s Use to Spinal Arthritis
An Eli Lilly drug first approved to treat psoriasis is delivering encouraging data from a late-stage study testing it as a potential new treatment for a form of arthritis affecting the spine. Indianapolis-based Lilly (NYSE: [[ticker:LLY]]) is trying to expand use of its drug ixekizumab (Taltz) to treat ankylosing spondylitis (AS), a condition that causes … Continue reading “Eli Lilly Builds Case to Expand Immune Drug’s Use to Spinal Arthritis”
Vertex Pharma Gets FDA Approval for Combo CF Drug, Sets $292,000 Price
[Updated, 2/13/18, see below] The FDA has approved a new Vertex Pharmaceuticals cystic fibrosis drug, clearing the way for the Boston company to bring to the market its third treatment for the inherited disorder. The new Vertex (NASDAQ: [[ticker:VRTX]]) drug pairs the already approved ivacaftor (Kalydeco) with the newly approved drug tezacaftor. Vertex set a … Continue reading “Vertex Pharma Gets FDA Approval for Combo CF Drug, Sets $292,000 Price”
CRISPR Therapeutics’ Lundberg Steps Down as Chief Scientific Officer
Bill Lundberg is leaving his position as chief scientific officer of CRISPR Therapeutics (NASDAQ: [[ticker:CRSP]]). CRISPR Therapeutics, which has operations in Switzerland and Cambridge, MA, said that Lundberg will continue as an advisor to the company and he is now head of its scientific advisory board. CRISPR Therapeutics develops treatments based on the CRISPR-Cas9 gene … Continue reading “CRISPR Therapeutics’ Lundberg Steps Down as Chief Scientific Officer”
Axovant CEO Hung, COO McCourt Resign After Brain Drug’s Failures
Axovant Sciences CEO David Hung has left the company, a move that comes a month after the firm halted development of a brain drug that failed in clinical trials. The shakeup of Basel, Switzerland-based Axovant (NASDAQ: [[ticker:AXON]]) includes the resignations of president and chief operating officer Marion McCourt, and three members of the board of directors. … Continue reading “Axovant CEO Hung, COO McCourt Resign After Brain Drug’s Failures”
Genentech’s Grossman Named Bellicum Pharma Chief Medical Officer
William Grossman has been appointed chief medical officer of Bellicum Pharmaceuticals (NASDAQ: [[ticker:BLCM]]). Grossman comes to the Houston biotech company from Genentech, where he was group medical director, cancer immunotherapy. Bellicum develops immunotherapies for cancers and blood disorders. In January, the company disclosed that the FDA halted a clinical trial testing its lead drug, BPX-501, … Continue reading “Genentech’s Grossman Named Bellicum Pharma Chief Medical Officer”
InVivo Therapeutics Chooses Richard Toselli for CEO Post
Richard Toselli has been named president and CEO of InVivo Therapeutics (NASDAQ: [[ticker:NVIV]]). Toselli had been acting CEO of the Cambridge, MA, medical device developer since December. Toselli will also continue as the company’s chief medical officer, a role the neurosurgeon took on when he joined InVivo last July. InVivo’s technology was co-invented by MIT … Continue reading “InVivo Therapeutics Chooses Richard Toselli for CEO Post”
Teva Migraine Drug Likely Delayed by Manufacturing Trouble
Teva Pharmaceutical’s bid to bring a new migraine drug to the market faces a possible delay due to manufacturing problems found with one of the company’s partners, and observers are skeptical about whether Teva will be able to get it over the finish line. The FDA was set to issue a decision about Teva’s (NYSE: … Continue reading “Teva Migraine Drug Likely Delayed by Manufacturing Trouble”
Intellia Exec Nessan Bermingham Rejoins Atlas as Venture Partner
Nessan Bermingham, the founding CEO of CRISPR drug maker Intellia Therapeutics (NASDAQ: [[ticker:NTLA]]), is returning to Atlas Venture as a venture partner. Bermingham led Intellia from its incubation in the Cambridge, MA, venture capital firm through its 2016 initial public stock offering. Bermingham first joined Atlas in 2002. In his new role, Atlas said Bermingham … Continue reading “Intellia Exec Nessan Bermingham Rejoins Atlas as Venture Partner”
Alexion’s Bedrosian Named Chief Medical Officer of Ultragenyx
Rare disease drug developer Ultragenyx Pharmaceutical (NASDAQ: [[ticker:RARE]]) has named Camille Bedrosian executive vice president and chief medical officer. Before joining the Novato, CA-based company, Bedrosian was senior vice president and chief medical officer of Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]) in New Haven, CT. Ultragenyx added gene therapy to its drug pipeline last fall through its … Continue reading “Alexion’s Bedrosian Named Chief Medical Officer of Ultragenyx”
Pompe Disease Patients on Amicus Drug Continue to Improve in Study
Patients treated with an experimental Amicus Therapeutics drug for Pompe disease continued to show improvement in their ability to walk, move, and breathe after as long as one year on the therapy, according to the latest clinical trial results from the rare disease drug developer. The open-label study is small, testing the drug in just … Continue reading “Pompe Disease Patients on Amicus Drug Continue to Improve in Study”
Theravance Snares $100M From Janssen in Stomach Drug Deal
Theravance Biopharma is teaming up with Janssen Biotech to develop a group of drugs for intestinal diseases such as ulcerative colitis and Crohn’s. Dublin, Ireland based-Theravance Biopharma (NASDAQ: [[ticker:TBPH]]), which has U.S. operations in South San Francisco, CA, will receive $100 million up front in the deal. The company could gain up to $900 million … Continue reading “Theravance Snares $100M From Janssen in Stomach Drug Deal”
Ex-MAP Execs Start Xoc with Plans to Leapfrog New Migraine Drugs
Patients should have better ways to prevent migraine headaches, says Scott Borland, president and CEO of Xoc Pharmaceuticals. Current generic drugs bring unwanted side effects. New options are on the way, but they will likely be expensive. Los Gatos, CA-based Xoc is now in the mix too. Xoc is developing a pill meant to prevent … Continue reading “Ex-MAP Execs Start Xoc with Plans to Leapfrog New Migraine Drugs”
Prothena Chief Medical Officer Sarah Noonberg Resigns
Prothena’s (NASDAQ: [[ticker:PRTA]]) chief medical officer, Sarah Noonberg, is stepping down from her post nine months after starting the job. Ireland-based Prothena, which has its U.S. operations in South San Francisco, CA, gave no reason for Noonberg’s departure other than to say that she decided to resign and will provide “transitional support” to the company … Continue reading “Prothena Chief Medical Officer Sarah Noonberg Resigns”
Dragonfly Therapeutics Appoints Cuillerot Chief Medical Officer
Cancer drug developer Dragonfly Therapeutics has appointed Jean-Marie Cuillerot to become its chief medical officer. Cuillerot’s experience in immunotherapy includes posts at Bristol-Myers Squibb (NYSE: [[ticker:BMY]]) and Merck Serono. Last year, Waltham, MA-based Dragonfly landed a partnership with Celgene (NASDAQ: [[ticker:CELG]]) that paid the startup $33 million up front to develop up to four blood … Continue reading “Dragonfly Therapeutics Appoints Cuillerot Chief Medical Officer”
Bristol-Myers Immune Drug Combo Hits Early Mark in Lung Cancer Study
[Updated 2/5/18, 2:36 p.m. See below.] A combination of two Bristol-Myers Squibb immunotherapies has achieved the main goal of a late-stage study in lung cancer, according to preliminary results the company released on Monday. But even though Bristol says the trial supports a new way of identifying patients who could best respond to its treatment, … Continue reading “Bristol-Myers Immune Drug Combo Hits Early Mark in Lung Cancer Study”
Surefire Medical Appoints Szela CEO, Chomas Shifts to CTO
Mary Szela has been named CEO and president of Denver-based Surefire Medical. Szela’s chief executive experience includes posts at Melinta Therapeutics (NASDAQ: [[ticker:MLNT]]) and later, Novelion Therapeutics (NASDAQ: [[ticker:NVLN]]). At Surefire, she succeeds James Chomas, the company’s founder and its chief executive since 2009. Chomas will move to a different role as chief technology and … Continue reading “Surefire Medical Appoints Szela CEO, Chomas Shifts to CTO”
Bio Roundup: Wilson’s Warning, Amazon’s Health Biz, Moderna Cash & More
The State of the Union address was…. long. At one hour and 20 minutes, President Trump fell about 9 minutes shy of the high mark. But those who stayed tuned in heard comments about several health policy matters. The president credited the FDA for a record number of generic drug approvals in 2017, which PwC … Continue reading “Bio Roundup: Wilson’s Warning, Amazon’s Health Biz, Moderna Cash & More”
Voyager Plans Executive Succession as CEO Paul Moves to New Role
Steven Paul, a founder of Voyager Therapeutics (NASDAQ: [[ticker:VYGR]]) and its current president and CEO, plans to move on to a new role as executive science advisor. Paul will remain CEO while the Cambridge, MA-gene therapy developer searches for his successor. Paul’s first position at Voyager was president of R&D. He became president and CEO … Continue reading “Voyager Plans Executive Succession as CEO Paul Moves to New Role”
Avrobio Raises $60M for Fabry Disease Gene Therapy, Rest of Pipeline
Avrobio has had encouraging early results testing its experimental gene therapy to treat Fabry disease, an inherited enzyme deficiency that leads to a dangerous fatty buildup in the body. As the biotech startup gears up for more tests, it now has $60 million more in financing to support those studies and the rest of its … Continue reading “Avrobio Raises $60M for Fabry Disease Gene Therapy, Rest of Pipeline”
Engine Biosciences Nabs $10M to Develop AI-Based Drug Discovery Tech
Engine Biosciences has raised $10 million in funding to further develop its artificial intelligence-based drug discovery tool. DHVC and 6 Dimensions Capital co-led the seed investment in the San Francisco-based company. Joining in the investment were WuXi AppTec, EDBI, Pavilion Capital, Baidu Ventures, WI Harper, and Nest.Bio Ventures. Engine says it has demonstrated that the … Continue reading “Engine Biosciences Nabs $10M to Develop AI-Based Drug Discovery Tech”
BridgeBio Picks Up Novartis Cancer Drug, Launches New Biotech Startup
BridgeBio Pharma has launched its latest biotech startup: a company built around an abandoned Novartis cancer drug candidate that is now backed by $65 million in fresh capital. The new company, QED Therapeutics, aims to pick up where Novartis (NYSE: [[ticker:NVS]]) left off. Novartis took the drug, infigratinib, as far as mid-stage clinical trials as … Continue reading “BridgeBio Picks Up Novartis Cancer Drug, Launches New Biotech Startup”
FDA Nixes Aradigm’s Inhaled Antibiotic, Asks for New Clinical Trial
Aradigm’s attempt to commercialize an inhalable version of a generic antibiotic as a treatment for chronic lung infections has stalled with the FDA’s rejection of the company’s drug approval application. Hayward, CA-based Aradigm (NASDAQ: [[ticker:ARDM]]) says it would be required to conduct another Phase 3 study of its version of ciprofloxacin (Linhaliq) in order to … Continue reading “FDA Nixes Aradigm’s Inhaled Antibiotic, Asks for New Clinical Trial”
Hugin to Retire from Celgene Board, CEO Alles Adds Chairman Role
Bob Hugin, chairman of Celgene’s (NASDAQ: [[ticker:CELG]]) board of directors, plans to retire effective Feb. 5. Mark Alles, CEO of the Summit, NJ, drugmaker, will take on the additional role of chairman after Hugin steps away. Hugin joined Celgene in 1999 as CFO. He was president and chief operating officer of the company from 2006 … Continue reading “Hugin to Retire from Celgene Board, CEO Alles Adds Chairman Role”
Luminex’s Tadd Lazarus Joins Clinical Genomics as Chief Medical Officer
Tadd Lazarus has joined cancer tests company Clinical Genomics as chief medical officer. Before coming to the Bridgewater, NJ-based company, Lazarus was senior vice president and chief medical officer for Luminex (NASDAQ: [[ticker:LMNX]]), an Austin, TX, firm that develops and sells biological testing technologies. Clinical Genomics markets tests for colorectal cancer.
Former Merrimack Exec Mulroy Surfaces as Partner Therapeutics CEO
Robert Mulroy is now CEO of Partner Therapeutics, a Boston cancer drug developer. Mulroy was co-founder and CEO of Cambridge-based Merrimack Pharmaceuticals (NASDAQ: [[ticker:MACK]]). Partner also named Debasish Roychowdhury its chief medical officer. Roychowdhury was most recently chief medical officer of San Diego-based Seragon Pharmaceuticals, which was acquired by Genentech. His experience includes senior management … Continue reading “Former Merrimack Exec Mulroy Surfaces as Partner Therapeutics CEO”
Acceleron Pharma Chief Medical Officer Sherman Plans Retirement
Matthew Sherman, chief medical officer of Acceleron Pharma (NASDAQ: [[ticker:XLRN]]), plans to retire from the Cambridge, MA-based drug developer. Acceleron says Sherman won’t step away until after the company releases initial data from the Phase 3 study for luspatercept, a drug it is testing in partnership with Celgene (NASDAQ: [[ticker:CELG]]) as a treatment for a rare … Continue reading “Acceleron Pharma Chief Medical Officer Sherman Plans Retirement”
Novartis Pays Spark $105M Up Front for Gene Therapy Rights Outside U.S.
Spark Therapeutics is licensing to Novartis the rights to its gene therapy outside of the U.S., a deal that puts the treatment for a rare, inherited form of blindness in the hands of a large pharmaceutical company with the resources to commercialize the drug globally. Novartis (NYSE: [[ticker:NVS]]) is paying Spark (NASDAQ: [[ticker:ONCE]]) $105 million … Continue reading “Novartis Pays Spark $105M Up Front for Gene Therapy Rights Outside U.S.”
Boston Scientific Pumps $90M Into Heart Device Startup Millipede
Boston Scientific is infusing medical device company Millipede with $90 million, an equity investment that comes with the option to acquire the startup outright. According to the agreement, Marlborough, MA-based Boston Scientific (NYSE: [[ticker:BSX]]) must exercise its option to acquire Millipede before the startup completes its ongoing clinical trial for its heart valve repair device—as … Continue reading “Boston Scientific Pumps $90M Into Heart Device Startup Millipede”
Tmunity Reels in $100M for “Next Generation” Cancer Immunotherapy
[Updated 1/23/18, 11:21 a.m. See below.] Two therapies from the emerging field of engineered T cells won FDA approval to treat blood cancers last year, and the scramble is on to treat more types of cancer. Led by Usman “Oz” Azam (pictured above), the executive who once led Novartis’s cell and gene therapy group, Tmunity … Continue reading “Tmunity Reels in $100M for “Next Generation” Cancer Immunotherapy”
BioCryst, Idera Plan Merger in Tie-Up of Rare Disease Drug Developers
BioCryst Pharmaceuticals and Idera Pharmaceuticals have struck a deal to combine into a single company focused on treatments for rare diseases. The stock deal announced Monday calls for each share of Research Triangle Park, NC-based BioCryst (NASDAQ: [[ticker:BCRX]]) to be exchanged for 0.50 shares of the new company. Idera (NASDAQ: [[ticker:IDRA]]) shareholders will get 0.20 … Continue reading “BioCryst, Idera Plan Merger in Tie-Up of Rare Disease Drug Developers”
Eli Lilly’s Eiry Roberts Joins Neurocrine as Chief Medical Officer
Eiry Roberts is Neurocrine Biosciences’ (NASDAQ: [[ticker:NBIX]]) new chief medical officer. Roberts comes to the San Diego biotech company from Eli Lilly (NYSE: [[ticker:LLY]]), where her roles included serving as vice president of clinical pharmacology, and vice president of R&D in the company’s biomedicines business unit. Roberts succeeds Christopher O’Brien, who will retire in February. … Continue reading “Eli Lilly’s Eiry Roberts Joins Neurocrine as Chief Medical Officer”
Trieza Therapeutics Appoints Jeno Gyuris Chief Scientific Officer
Trieza Therapeutics has named Jeno Gyuris its chief scientific officer. Cambridge, MA-based Trieza is developing cancer immunotherapies that use viruses to prompt an anti-tumor response. Gyuris’ experience includes senior scientific posts at two other Boston-area biotechs, Aveo Pharmaceuticals (NASDAQ: [[ticker:AVEO]]) and Quiet Therapeutics.
Pandion Raises $58M to Bring Cancer-Fighting Tactics to Immune Disorders
Many drugs for inflammatory and autoimmune disorders work by suppressing the immune system, an approach that puts patients at risk of infection among other side effects. Pandion Therapeutics is developing antibody drugs that it says could instead work with the immune system, potentially offering a safer, more targeted treatment. The Cambridge, MA, biotech has now … Continue reading “Pandion Raises $58M to Bring Cancer-Fighting Tactics to Immune Disorders”
Eiger Bio’s Hypertension Drug Flunks Phase 2 Trial, Shares Tumble
An Eiger BioPharmaceuticals drug being tested for the treatment of pulmonary arterial hypertension has failed a mid-stage study, and the drug developer says it will stop work on the compound for that condition. News of the clinical trial failure cut the value of shares in Palo Alto, CA, based Eiger (NASDAQ: [[ticker:EIGR]]) nearly in half. … Continue reading “Eiger Bio’s Hypertension Drug Flunks Phase 2 Trial, Shares Tumble”
Genentech’s Cindy Elkins Joins Juno Tx as Chief Information Officer
Juno Therapeutics (NASDAQ: [[ticker:JUNO]]) has appointed Cindy Elkins to serve as chief information officer. Elkins comes to the Seattle cancer immunotherapy developer from Genentech, where she was vice president, IT, for the Americas. Before Genentech, Elkins worked at software and IT services firm Ariba.
OrphoMed Names Mark Sostek Chief Medical Officer
Mark Sostek is joining San Francisco-based drug developer OrphoMed as chief medical officer. Sostek most recently worked at Pfizer (NYSE: [[ticker:PFE]]) in its inflammation and immunology research unit. Before that, he was global clinical leader for gastrointestinal programs at AstraZeneca (NYSE: [[ticker:AZN]]). OrphoMed’s lead drug candidate, ORP-101, is in early-stage clinical testing for irritable bowel … Continue reading “OrphoMed Names Mark Sostek Chief Medical Officer”
Bio Roundup: #JPM18, Axovant’s Fall, CRISPR Caveat, Impact M&A & More
Have you gotten your flu shot yet this year? This winter’s flu season is shaping up to be a particularly nasty one and the Centers for Disease Control and Prevention this week upped its tally of states reporting widespread flu activity to 46. Flu awareness was top of mind at the J.P. Morgan Healthcare Conference … Continue reading “Bio Roundup: #JPM18, Axovant’s Fall, CRISPR Caveat, Impact M&A & More”
BioClin Therapeutics Adds Gilead’s Steve Abella to Executive Team
Esteban (Steve) Abella has been appointed chief medical officer of San Ramon, CA-based BioClin Therapeutics. Abella most recently worked at Gilead Sciences (NASDAQ: [[ticker:GILD]]), where he was a senior director leading the company’s non-Hodgkin lymphoma and leukemia efforts. BioClin also named Graeme Currie to the chief operating officer post. Currie’s experience includes senior leadership positions … Continue reading “BioClin Therapeutics Adds Gilead’s Steve Abella to Executive Team”
AOBiome Therapeutics Promotes Todd Krueger to CEO
Todd Krueger has been named CEO of AOBiome Therapeutics. In addition to serving as CEO, Krueger will keep his current role as president of the Cambridge, MA, company, a position he has held since 2016. Krueger joined AOBiome in 2015 as chief business officer. AOBiome is developing microbiome treatments for local and systemic inflammatory conditions.
Eye Drug Delivery Firm Eyenovia Sets IPO Range as Plans Come Into Focus
Eyenovia, a startup that has adapted an inkjet printing technique into a way to deliver drugs to the eye, is providing more clarity on an initial public offering intended to finance late-stage clinical testing of its technology. New York-based Eyenovia plans to offer 2.73 million shares priced between $10 and $12 each, according to an … Continue reading “Eye Drug Delivery Firm Eyenovia Sets IPO Range as Plans Come Into Focus”
Ag Startup Inocucor Adds $9.5M for Microbes that Improve Yields, Soil
A growing number of agtech startups are researching biological products that work with the community of microorganisms in and around plants. Denver-based Inocucor has developed microbes intended to improve plant and soil health and it now has $9.5 million in additional financing to support its efforts to bring these products to crops. The latest investment … Continue reading “Ag Startup Inocucor Adds $9.5M for Microbes that Improve Yields, Soil”
Allergan’s David Melnick Joins Spero Tx as Chief Medical Officer
David Melnick has joined Spero Therapeutics (NASDAQ: [[ticker:SPRO]]) to become the Cambridge, MA, company’s chief medical officer. Melnick served as vice president of clinical development for anti-infectives at Allergan (NYSE: [[ticker:AGN]]) since 2015. Spero has two clinical-stage antibiotics that the company hopes can help address the growing problem of drug-resistant bacteria.
PellePharm Appoints Sanuj Ravindran to CEO Post
PellePharm has appointed Sanuj Ravindran CEO of the Menlo Park, CA, company. Ravindran comes to PellePharm from San Diego-based aTyr Pharma (NASDAQ: [[ticker:LIFE]]), where he was chief business officer. Before working at aTyr, Ravindran was senior vice president of corporate development for The Medicines Company (NASDAQ: [[ticker:MDCO]]). PellePharm develops drugs to treat rare skin disorders. … Continue reading “PellePharm Appoints Sanuj Ravindran to CEO Post”
Axovant Neuro Drug Stumbles and Falls in Phase 2, Shares Drop 50%
A drug intended to treat a form of dementia has failed in a pair of mid-stage clinical studies, and the company that developed it, Axovant, now says it will stop work on the compound altogether. Axovant (NASDAQ: [[ticker:AXON]]) was testing its drug intepirdine as a treatment for dementia with Lewy bodies (DLB), a progressive brain … Continue reading “Axovant Neuro Drug Stumbles and Falls in Phase 2, Shares Drop 50%”
Alder Plans for FDA Filing After Migraine Drug Posts Strong Results
Alder Biopharmaceuticals’ migraine-prevention drug hit its main goal in a late-stage study, and the drug developer these early results keep it on track to file for FDA approval later this year. Bothell, WA-based Alder (NASDAQ: [[ticker:ALDR]]) tested its drug, eptinezumab, in patients who have chronic migraine—more than 15 headaches per month. The company reported that … Continue reading “Alder Plans for FDA Filing After Migraine Drug Posts Strong Results”
Sigilon Brings on Eli Lilly’s Moller as Chief Scientific Officer
David Moller has joined Sigilon Therapeutics to become the company’s chief scientific officer. Moller comes to the Cambridge, MA, drug developer from Eli Lilly (NYSE: [[ticker:LLY]]), where he was vice president of business development for emerging technology and innovation. Last year, Sigilon raised $23.5 million in a Series A financing round to bring its technology … Continue reading “Sigilon Brings on Eli Lilly’s Moller as Chief Scientific Officer”
Biogen’s Jean-Paul Kress Joins Syntimmune as President and CEO
Jean-Paul Kress has been appointed president and CEO of Syntimmune. Kress will also serve as a director of the New York-based drug developer. He replaces David de Graaf, who has stepped down as CEO and member of the company’s board of directors. Kress comes to Syntimmune from Cambridge, MA-based Biogen (NASDAQ: [[ticker:BIIB]]), where he was … Continue reading “Biogen’s Jean-Paul Kress Joins Syntimmune as President and CEO”
Denali, Takeda Reach $155M Deal to Develop Alzheimer’s Drug & Others
Denali Therapeutics and Takeda Pharmaceutical have agreed to work together to develop up to three drugs for neurodegenerative diseases, including a compound that could treat Alzheimer’s disease. The deal announced Friday calls for Takeda to pay Denali (NASDAQ: [[ticker:DNLI]]) $155 million, a combination of cash and stock purchases. If South San Francisco, CA-based Denali successfully … Continue reading “Denali, Takeda Reach $155M Deal to Develop Alzheimer’s Drug & Others”
Biogen’s Jean-Paul Kress Joins Syntimmune as President and CEO
Jean-Paul Kress has been appointed president and CEO of Syntimmune. Kress will also serve as a director of the New York-based drug developer. He replaces David de Graaf, who has stepped down as CEO and a member of the company’s board of directors. Kress comes to Syntimmune from Cambridge, MA-based Biogen (NASDAQ: [[ticker:BIIB]]), where he … Continue reading “Biogen’s Jean-Paul Kress Joins Syntimmune as President and CEO”